1. Carfilzomib in relapsed or refractory multiple myeloma patients with early or late relapse following prior therapy: A subgroup analysis of the randomized phase 3 ASPIRE and ENDEAVOR trials. Issue 2 (15th February 2018) Authors: Mateos, Maria‐Victoria; Goldschmidt, Hartmut; San‐Miguel, Jesus; Mikhael, Joseph; DeCosta, Lucy; Zhou, Lifen; Obreja, Mihaela; Blaedel, Julie; Szabo, Zsolt; Leleu, Xavier Journal: Hematological oncology Issue: Volume 36:Issue 2(2018) Page Start: 463 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Carfilzomib, dexamethasone and daratumumab in relapsed or refractory multiple myeloma: results of the phase III study CANDOR by prior lines of therapy. (28th May 2021) Authors: Quach, Hang; Nooka, Ajay; Samoylova, Olga; Venner, Christopher P.; Kim, Kihyun; Facon, Thierry; Spencer, Andrew; Usmani, Saad Z.; Grosicki, Sebastian; Suzuki, Kenshi; Delimpasi, Sosana; Weisel, Katja; Obreja, Mihaela; Zahlten‐Kumeli, Anita; Mateos, Maria‐Victoria Journal: British journal of haematology Issue: Volume 194:Number 4(2021) Page Start: 784 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study. (17th February 2017) Authors: Dimopoulos, Meletios A.; Stewart, A. Keith; Masszi, Tamás; Špička, Ivan; Oriol, Albert; Hájek, Roman; Rosiñol, Laura; Siegel, David; Mihaylov, Georgi G.; Goranova‐Marinova, Vesselina; Rajnics, Péter; Suvorov, Aleksandr; Niesvizky, Ruben; Jakubowiak, Andrzej; San‐Miguel, Jesus; Ludwig, Heinz; Palu... Journal: British journal of haematology Issue: Volume 177:Number 3(2017) Page Start: 404 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Efficacy and safety of weekly carfilzomib (70 mg/m2), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option: a cross-study comparison of the CANDOR and EQUULEUS studies. Issue 2 (28th January 2021) Authors: Leleu, Xavier; Beksac, Meral; Chou, Takaaki; Dimopoulos, Meletios; Yoon, Sung-Soo; Prince, H. Miles; Pour, Ludek; Shelekhova, Tatiana; Chari, Ajai; Khurana, Monica; Zhang, Jianqi; Obreja, Mihaela; Qi, Ming; Oriol, Albert; Siegel, David Journal: Leukemia & lymphoma Issue: Volume 62:Issue 2(2021) Page Start: 358 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Post-protocol therapy and informative censoring in the CANDOR study – Authors' reply. Issue 3 (March 2022) Authors: Usmani, Saad Z; Li, Chuang; Obreja, Mihaela; Dimopoulos, Meletios Journal: Lancet oncology Issue: Volume 23:Issue 3(2022) Page Start: e98 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗